incorporated in 2018, cytomed therapeutics is a spin-off from singapore’s agency for science, technology and research ( a*star) and focuses on translating its patented technologies into gamma delta (γδ) t cell- and natural killer (nk) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. we also engage in generating induced pluripotent stem cells (ipscs) and translating them into “off-the-shelf” cellular therapeutics using our proprietary technologies for our customers.
Company profile
Ticker
GDTC
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CytoMed Therapeutics Pte. Ltd.
SEC CIK
GDTC stock data
Latest filings (excl ownership)
6-K/A
Current report (foreign) (amended)
24 Jun 24
6-K
Current report (foreign)
20 Jun 24
6-K
Current report (foreign)
24 May 24
6-K/A
Current report (foreign) (amended)
25 Apr 24
6-K
Current report (foreign)
24 Apr 24
20-F
2023 FY
Annual report (foreign)
22 Apr 24
6-K
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
18 Mar 24
6-K
Current report (foreign)
4 Mar 24
6-K
Malaysian Patent Granted for CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29 Jan 24
6-K
Current report (foreign)
17 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q1 2024
51.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 23.96 mm |
Total shares | 5.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Chee Kong Choo | 4.65 mm | $18.61 mm |
mDR | 1.34 mm | $5.35 mm |